

Ophthalmic Drugs Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018

Single User License: US \$ 4595

Multi User License: US \$ 7595

Corporate User License: US \$ 10595

[Buy Now](#)

[Request Sample](#)

Published Date: Jan 2014

72 Pages Report

REPORT DESCRIPTION

Ophthalmic Drugs Market is Expected to Reach USD 21.6 Billion Globally in 2018: Transparency Market Research

According to a new market report published by Transparency Market Research "**Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti allergy/ inflammatory/ infective, Retinal Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018**" the global ophthalmic drugs market was valued at USD 16 billion in 2012 and is expected to grow at a CAGR of 5.2% from 2013 to 2018, to reach an estimated value of USD 21.6 billion in 2018.

Globally, the ophthalmic drugs market is witnessing significant growth due to increasing prevalence of eye disorders such as diabetic retinopathy and macular degeneration. As a result, this market is expected to grow at a CAGR of about 5.2% during 2013 - 2018.

Some of the key driving factors for the ophthalmic drugs market are rising prevalence of global aging population, increasing government initiatives towards healthcare infrastructure in developing countries (such as India and China), technological changes in drug delivery technique, and increasing prevalence of lifestyle associated diseases. However, the market faces some restraints such as lack of awareness among people regarding eye disorders, drying pipeline of ophthalmic drugs, patent expiration of blockbuster ophthalmic drugs and absence of health insurance in developing countries.

North America, including the US has the largest ophthalmic drugs market. Asia is the fastest growing ophthalmic drugs market. Some of the fastest growing markets for ophthalmic drugs are China, India, other countries in South East Asia and the Eastern Mediterranean. As per WHO estimates in 2010, in the next nine years, the number of blind people aged 50 years and above will grow in these regions, thereby increasing the demand for ophthalmic drugs. On the other hand, in developed regions such as North America and Western Europe, rising efforts towards prevention of blindness among the aging population has emerged as a key driver for the market.

Glaucoma has the largest market share in the ophthalmic drugs market and it is expected to grow at a CAGR of about 4.2% during 2013 - 2018. Various ophthalmic drug companies are increasing their focus on combination therapy, which involves use of more than one medication for specific retinal disorders. Most of these combination therapies are used as first line treatment in patients with high level of intraocular pressure. Combination therapy has various advantages over traditional medication such as reduced frequency of eye drop application, improved patient compliance and efficacy.

Novartis (Alcon) is the leading player in the global ophthalmic drugs market while other major players include Allergan, Santen, Pfizer, Merck and Roche.

The global ophthalmic drugs market is segmented as follows:

Ophthalmic Drugs Market, By Treatment Drugs

- Dry Eye Drugs
- Retinal Drugs
- Anti-inflammatory/allergy/infective Drugs
- Anti-glaucoma Drugs

Ophthalmic Drugs Market, By Types

- Prescription Drugs
- OTC Drugs

Ophthalmic Drugs Market, by Geography

- North America
- US
- Europe
- Germany
- UK
- France
- Asia Pacific
- Japan

- China
- India
- Rest of the World (RoW)

TABLE OF CONTENTS

Chapter 1 Preface 8

1.1 Report Description 8

1.2 Research Methodology 8

Chapter 2 Executive Summary 10

Chapter 3 Ophthalmic Drugs – Industry Analysis 11

3.1 Introduction 11

3.2 Market Drivers and Opportunities 11

3.2.1 Increasing prevalence of eye disorders 12

3.2.2 Global aging population 12

3.2.3 Rising government initiatives towards healthcare infrastructure in developing countries 13

3.2.4 Technological changes in drug delivery techniques 14

3.2.5 Increasing prevalence of lifestyle associated diseases 14

3.3 Restraints and Challenges 15

3.3.1 Lack of awareness among people regarding eye disorders 15

3.3.2 Drying pipeline of ophthalmic drugs 15

3.3.3 Patent expiration of blockbuster ophthalmic drugs 16

3.3.4 Absence of health insurance in developing countries 16

Chapter 4 Ophthalmic Drugs Market Trends 18

4.1 Increased focus on combination therapy 18

4.2 Increasing mergers and acquisitions contribute to the growth of ophthalmic drugs market 18

Browse the full Ophthalmic Drugs Market Report with TOC:

<http://www.transparencymarketresearch.com/ophthalmic-drugs-market.html>

Chapter 5 Porter's Five Force Analysis 20

5.1 Bargaining power of buyers 20

5.2 Bargaining power of suppliers 21

5.3 Threat of new entrants 21

5.4 Threat from substitutes 21

5.5 Degree of competition 21

Chapter 6 Global Market Size and Forecast 22

Chapter 7 Ophthalmic Drugs Market – Treatment Drugs 25

7.1 Dry eye drugs 25

7.1.1 Existing 25

7.1.2 Pipeline 26

7.2 Retinal drugs 27

7.2.1 Existing 27

7.2.2 Pipeline 28

7.3 Ophthalmic anti-allergy/ inflammatory/ infective drugs 29

7.3.1 Existing 29

7.3.2 Pipeline 30

7.4 Anti-glaucoma drugs 31

7.4.1 Existing 31

7.4.2 Pipeline 32

Related & Recently Published Reports by Transparency Market Research

Nonwoven Materials & Products Market:

<http://www.transparencymarketresearch.com/nonwoven-materials-and-products.html>

Methyl Ethyl Ketone Market: <http://www.transparencymarketresearch.com/methyl-ethyl-ketone.html>

Power Rental Market: <http://www.transparencymarketresearch.com/power-rental-market.html>

Drugs of Abuse Testing Market: <http://www.transparencymarketresearch.com/drugs-abuse-testing-market.html>

Chapter 8 Ophthalmic Drugs Market: Regional Analysis 34

8.1 Scenario in North America 34

8.1.1 Scenario in the US 36

8.2 Scenario in Europe 38

8.2.1 Scenario in France 41

8.2.2 Scenario in Germany 42

8.2.3 Scenario in the UK 44

8.3 Scenario in Asia Pacific 46

8.3.1 Scenario in India 49

8.3.2 Scenario in China 50

8.3.3 Scenario in Japan 52

Chapter 9 Prescription vs. Over the Counter Drugs 55

Chapter 10 Competitive Landscape 57

Chapter 11 Company Profiles 62

11.1 Santen Pharmaceutical 62

11.1.1 Overview 62

11.1.2 Products and segments 62

11.1.3	Financial Performance	62
11.2	Pfizer	63
11.2.1	Overview	63
11.2.2	Products & Segments	63
11.2.3	Financial Performance	63
11.3	Novartis	64
11.3.1	Overview	64
11.3.2	Products & Segments	64
11.3.3	Financial Performance	65
11.4	Merck	66
11.4.1	Overview	66
11.4.2	Products & Segments	66
11.4.3	Financial Performance	66
11.5	Roche	68
11.5.1	Overview	68
11.5.2	Products & Segments	68
11.5.3	Financial Performance	68
11.6	Allergan	70
11.6.1	Overview	70
11.6.2	Products & Segments	70
11.6.3	Financial Performance	70



About Us:

Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Website: <http://www.transparencymarketresearch.com/>

Browse the full Ophthalmic Drugs Market Report with TOC:

<http://www.transparencymarketresearch.com/ophthalmic-drugs-market.html>

Related Blogs:

<https://vaibhavmondhe.wordpress.com>
<https://usamarketresearch.wordpress.com/>
<https://pharmaceuticalmarkets.wordpress.com/>
<https://medicaldevicesreports.wordpress.com/>
<https://chemicalandmaterials.wordpress.com/>